United States
Code Biotherapeutics is a trailblazer in the field of genetic medicine, dedicated to the development of precision therapies for individuals affected by genetic disorders. Founded in 2020, this United States-based company operates at the intersection of Biotechnology, Health Care, and Life Sciences.
The driving force of Code Biotherapeutics is its proprietary 3DNA® platform. This innovative, multivalent, synthetic DNA delivery technology is engineered to circumvent the traditional challenges associated with genetic medicine delivery, such as dose-related toxicity, off-target effects, and vector manufacturing complexity. It also boasts improved bioavailability and the unique ability to re-dose.
The company's internal pipeline focuses on diseases like Duchenne’s Muscular Dystrophy (DMD) and extends research to organs such as the lungs, pancreas, and liver. In a significant show of confidence, Code Biotherapeutics secured a $75.00M Series A investment in June 2022 from prominent investors, including 4BIO Capital, Amgen Ventures, and Takeda Ventures.
